Which Telehealth Providers Can Prescribe ADHD Stimulants in Your State? (2026)
Access to stimulant medications for ADHD — Adderall, Vyvanse, Ritalin, Concerta — is one of the most practically important questions for adults seeking online ADHD care. The answer depends on three intersecting variables: the prescribing rules in your state, the DEA registration of the specific telehealth platform, and the current status of federal telehealth prescribing policy.
This guide maps out what is actually available by state, which platforms prescribe stimulants, and what regulatory changes to watch.
Why Stimulant Prescribing Varies by State
Schedule II controlled substances — the DEA classification for most ADHD stimulants — are subject to stricter prescribing rules than non-controlled medications. Key factors:
- DEA registration by state: A prescriber must hold a DEA registration in the state where the patient is physically located at the time of the prescription. National telehealth platforms maintain multi-state DEA registrations but individual prescribers may not be credentialed in every state.
- The Ryan Haight Act: Federal law generally requires an in-person evaluation before a controlled substance can be prescribed via telemedicine. A COVID-era DEA exception has allowed fully virtual stimulant prescriptions since 2020.
- Post-pandemic rulemaking: The DEA's proposed rules for permanent telehealth prescribing of controlled substances (proposed 2023, re-proposed 2024) will shape what is allowed after the COVID exception expires. Final rules are pending as of April 2026.
Telehealth Platforms That Prescribe Stimulants
The table below shows which platforms offer stimulant prescriptions for ADHD and their known state availability as of July 2026.
| Platform | Stimulants Prescribed | States Available | Typical Wait |
|---|---|---|---|
| Talkiatry | Yes (full formulary) | 45+ states | 1–2 weeks |
| Cerebral | No (non-stimulants only) | 13 states | 1–2 weeks |
| ADHD Online | Yes (after evaluation) | Most states | 1 week |
| Minded | Yes | 15+ states | 1 week |
| Ahead | Yes | Select states | 1–2 weeks |
| Brightside Health | Psychiatry only (no ADHD focus) | 45+ states | 3–5 days |
Stimulant availability subject to DEA rulemaking changes. Verify current status directly with each platform.
State-by-State Prescribing Availability
The following table summarizes how many telehealth platforms can prescribe Schedule II ADHD stimulants in each state, based on publicly available information as of July 2026.
| State | Platforms Available | Notes |
|---|---|---|
| California | 4+ | Large prescriber network; strong access |
| Texas | 4+ | Large prescriber network; strong access |
| Florida | 4+ | Large prescriber network; strong access |
| New York | 4+ | Large prescriber network; strong access |
| Illinois | 4+ | Strong access |
| Pennsylvania | 3+ | Moderate access |
| Ohio | 3+ | Moderate access |
| Georgia | 3+ | Moderate access |
| North Carolina | 3+ | Moderate access |
| Michigan | 2–3 | Limited options |
| New Jersey | 3+ | Moderate access |
| Virginia | 3+ | Moderate access |
| Massachusetts | 2–3 | Limited options |
| Arizona | 3+ | Moderate access |
| Washington | 3+ | Moderate access |
| Colorado | 3+ | Moderate access |
| Tennessee | 2–3 | Limited options |
| Indiana | 2–3 | Limited options |
| Minnesota | 1–2 | Very limited |
| Wisconsin | 1–2 | Very limited |
| Kentucky | 2–3 | Limited options |
| Missouri | 2–3 | Limited options |
| Nevada | 1–2 | Limited — verify current state availability directly |
| Alabama | 2 | Limited |
| Arkansas | 2 | Limited |
| Mississippi | 2 | Limited |
| Montana | 1–2 | Very limited |
| Wyoming | 1–2 | Very limited |
| North Dakota | 1–2 | Very limited |
| South Dakota | 1–2 | Very limited |
| Alaska | 1–2 | Very limited |
| Hawaii | 1–2 | Very limited |
| Vermont | 1–2 | Very limited |
| West Virginia | 1–2 | Very limited |
This table will be updated as platforms expand state coverage. "Available platforms" counts platforms confirmed to prescribe stimulants in that state — not all telehealth providers that offer ADHD care.
The Ryan Haight Act: What Patients Need to Know in 2026
The Ryan Haight Online Pharmacy Consumer Protection Act of 2008 was written to prevent prescription drug mills — fly-by-night websites prescribing controlled substances without any clinical relationship. It requires an in-person evaluation before a controlled substance can be prescribed via telemedicine.
The COVID-19 Public Health Emergency (PHE) created a DEA exception that waived this requirement, allowing platforms to prescribe stimulants through fully virtual consultations. That exception has been extended multiple times.
What happens next: The DEA proposed a permanent "telemedicine prescribing" framework in 2023. Under the proposed rules, platforms would need to either maintain a "qualified telemedicine company" registration or require patients to complete an in-person evaluation with a separate provider before receiving a telehealth stimulant prescription. Final rules have not been published as of April 2026.
What this means for patients: Federal telehealth prescribing rules remain in flux. Patients who already have a clinical relationship with a telehealth prescriber may be able to continue care under existing rules while final regulations are pending. Check each platform's current policy, as approaches vary.
Non-Stimulant Alternatives Available Nationwide
For patients in states with limited stimulant prescribing options, non-stimulant ADHD medications — Strattera (atomoxetine), Intuniv (guanfacine), Kapvay (clonidine), Qelbree (viloxazine) — are available without the Schedule II restrictions. Platforms like Cerebral prescribe non-stimulant ADHD medications in 13 states and may be a practical starting point while patients pursue stimulant options.
Browse ADHD telehealth providers on VirtualCareFinder to compare options in your state.